PRPaul J. Ross

Paul J. Ross

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Paul J. Ross has a total of 486 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Advanced extrahepatic cholangiocarcinoma and gallbladder cancer: Post-hoc analysis of the ABC-01, -02 and -03 clinical trials

    by Angela Lamarca, Paul Ross, Harpreet S. Wasan, Richard A. Hubner, Mairéad G. McNamara, Andre Lopes, Daniel H. Palmer, Juan W. Valle, John Bridgewater


  • Open Access

    Pattern of progression and post-progression survival following transarterial embolisation: An analysis of the TACE-2 and TACTICS trials

    by Jack Shi Jie Yuan-Doré, Memuna Rashid, Kazuomi Ueshima, Andre Lopes, Yuk Ting Ma, Paul Ross, Daniel Palmer, Masatoshi Kudo, Tim Meyer


  • Open Access

    Selective Internal Radiation Therapy (SIRT) for Hepatocellular Carcinoma: Real-World Experience from a Tertiary Care Centre

    by I. Ergenc, M. Guerra Veloz, M. Seager, N. Heraghty, N. Kibriya, J. Green, A. Koundouraki, S. Selemani, K. Menon, R. Miquel, et al.

    Background: Selective internal radiation therapy (SIRT) with yttrium-90 microspheres has become an established locoregional treatment for hepatocellular carcinoma (HCC). Nevertheless, real-world data on clinical outcomes, including efficacy, safety, and prognostic determinants, remain limited. Methods: This study retrospectively analysed 56 patients with radiologically and/or histologically confirmed HCC who underwent SIRT at a tertiary referral centre. Baseline demographics, clinical information, tumour characteristics, procedural data, and follow-up outcomes were recorded. The primary endpoints were overall survival (OS) and progression-free survival (PFS). Secondary outcomes included radiological response (mRECIST), histological necrosis, and treatment-related toxicity. Prognostic pathways were explored using structural equation modelling (SEM). Results: The mean age at the beginning of SIRT was 65.0 ± 11.6 years; most patients were male (87.5%) and had preserved liver function (mean ALBI −2.9 ± 0.4). BCLC staging distribution was 50% stage A, 32.1% stage B, and 17.9% stage C. According to mRECIST criteria at 6 months, 15.2% achieved complete response (CR), 47.8% partial response (PR), 30% stable disease (SD), and 7% progressive disease (PD). Median OS was 19 months (12–32) for BCLC stage A, 28 months (3–42) for stage B, and 19 months (12–56) for stage C (log-rank p = 0.743). SEM identified diffuse tumour morphology as the most significant predictor of poor prognosis. Radical treatments were performed in 28% of patients, including four liver transplants and ten resections. Adverse events occurred in 11 patients, of which 7 were Clavien–Dindo grade I and 4 were grade II. Conclusions: In this real-world HCC group, SIRT provided durable tumour control and survival with excellent tolerability.


  • Open Access

    Advanced ampullary cancer: post-hoc analysis of the ABC-01, ABC-02, and ABC-03 clinical trials

    by Angela Lamarca, Paul Ross, Harpreet S Wasan, Richard A Hubner, Mairéad G McNamara, Andre Lopes, Daniel Palmer, Juan W Valle, John Bridgewater

    Ampullary carcinoma (AC) is a rare malignancy. It is often classified within biliary tract cancers (BTC) but lacks dedicated treatment guidelines. This post-hoc analysis evaluated outcomes of patients with advanced AC enrolled in the ABC-01, ABC-02, and ABC-03 clinical trials to provide reference data for future studies. All patients with advanced AC formed the “Descriptive cohort,” while those AC treated with cisplatin–gemcitabine (CisGem) comprised the “CisGem-treated cohort.” Among 534 trial participants, 28 (5.24%) had AC, and 17 received CisGem. The median age was 63.93 years, and 75.00% were male. Most patients had metastatic disease at baseline (89.29%). Median follow-up for the CisGem-treated cohort was 10.23 months (95% CI 5.98-14.43). The objective response rate was 23.52%, and disease control was achieved in 58.82% of patients. Estimated median progression-free survival (PFS) and overall survival (OS) were 7.98 months (95% CI, 6.86-8.44) and 11.76 months (95% CI, 5.94-14.88), respectively, comparable to outcomes in other BTCs. No reliable prognostic or predictive factors for PFS, OS, or ORR were identified, likely reflecting the small sample size. This analysis underscores the rarity of advanced AC and the challenges in recruiting adequate numbers for dedicated trials. While CisGem remains an appropriate standard-of-care regimen, modest survival outcomes highlight the need for improved therapies. Molecular profiling has revealed potentially actionable alterations, including HER2 amplification and KRAS mutations, supporting precision oncology approaches. This study provides the most comprehensive reference dataset to date for advanced AC treated with CisGem and emphasizes the importance of international collaboration and molecularly guided research to improve outcomes in this rare malignancy.

  • Open Access

    Guy’s Cancer Cohort: Guy’s Cancer Centre’s Real-World Evidence Programme 5 years later

    by C.L. Moss, B. Russell, G. George, J. Handford, E. Josephides, S. Green, A. Mera, K. Haire, A. Igra, M. Gladman, et al.

  • Implementation of mass pharmacogenetic testing : Dihydropyrimidine dehydrogenase testing prior to fluoropyrimidine treatment for patients

    by Nisha Shaunak, Jessica Keen, Anna Kim, Munir Pirmohamed, William G. Newman, Paul J. Ross

    Aims: Pharmacogenomics enables personalization of drug therapy improving effectiveness and/or safety. Dihydropyrimidine dehydrogenase [DPYD] testing prior to fluoropyrimidine chemotherapy was commissioned by NHS England in response to an update from the Medicines and Healthcare products Regulatory Agency. Methods: A questionnaire developed and approved by the National DPYD Working Group investigated processes of testing, receiving and responding to results. The survey was distributed to Genomics Medicine Service Alliance (GMSA) Clinical Directors and Pharmacy Senior Responsible Officers for dissemination in their geography. Data were collected June–September 2021. All hospitals delivering fluoropyrimidines across the UK were invited to participate. Results: 131/138 (94.9%) organizations reported testing all patients receiving fluoropyrimidines. In England 76.7% of hospitals sent samples to centrally commissioned genomics laboratories. In the devolved nations, 73.9% sent samples to regional genomics laboratories. Multidisciplinary staff including oncologists, independent non‐medical prescribers, clinical nurse specialists, screening pharmacists and chemotherapy nurses requested the test, checked and actioned the result. Self‐reported turnaround times varied from 10 days. Conclusion: Through multiprofessional, national collaboration, this is the first report studying the large‐scale rollout of a nationally commissioned pharmacogenetic test. Whilst DPYD testing has been successfully implemented, there is a need to standardize and improve end‐to‐end turnaround times. This has led to the development of a best practice pathway. Critically, GMSAs must build on this implementation to deliver its priorities, in supporting equitable access to future pharmacogenomic testing across a wider cohort of therapies.


  • Open Access

    Large-Scale Pharmacogenomics Analysis of Patients With Cancer Within the 100,000 Genomes Project Combining Whole-Genome Sequencing and Medical Records to Inform Clinical Practice

    by Ivone U.S. Leong, Claudia P. Cabrera, Valentina Cipriani, Paul J. Ross, Richard M. Turner, Alex Stuckey, Sonali Sanghvi, Dorota Pasko, Loukas Moutsianas, Christopher A. Odhams, et al.

    PURPOSE: As part of the 100,000 Genomes Project, we set out to assess the potential viability and clinical impact of reporting genetic variants associated with drug-induced toxicity for patients with cancer recruited for whole-genome sequencing (WGS) as part of a genomic medicine service. METHODS: Germline WGS from 76,805 participants was analyzed for pharmacogenetic (PGx) variants in four genes ( DPYD , NUDT15 , TPMT , UGT1A1 ) associated with toxicity induced by five drugs used in cancer treatment (capecitabine, fluorouracil, mercaptopurine, thioguanine, irinotecan). Linking genomic data with prescribing and hospital incidence records, a phenome-wide association study (PheWAS) was performed to identify whether phenotypes indicative of adverse drug reactions (ADRs) were enriched in drug-exposed individuals with the relevant PGx variants. In a subset of 7,081 patients with cancer, DPYD variants were reported back to clinicians and outcomes were collected. RESULTS: We identified clinically relevant PGx variants across the four genes in 62.7% of participants in our cohort. Extending this to annual prescription numbers in England for the drugs affected by these PGx variants, approximately 14,540 patients per year could potentially benefit from a reduced dose or alternative drug to reduce the risk of ADRs. Validating PGx associations in a real-world data set, we found a significant association between PGx variants in DPYD and toxicity-related phenotypes in patients treated with capecitabine or fluorouracil. Reported DPYD variants were deemed informative for clinical decision making in a majority of cases. CONCLUSION: Reporting PGx variants from germline WGS relevant to patients with cancer alongside primary findings related to their cancer can be clinically informative, informing prescribing to reduce the risk of ADRs. Extending the range of actionable variants to those found in patients of non-European ancestry is important and will extend the potential clinical impact.


  • A phase III randomized study of first-line NUC-1031/cisplatin vs. gemcitabine/cisplatin in advanced biliary tract cancer

    by Jennifer J. Knox, Mairéad G. McNamara, Igor S. Bazin, Do-Youn Oh, Oleksii. Zubkov, Valeriy Breder, Li-Yuan Bai, Alan Christie, Lipika Goyal, David P. Cosgrove, et al.


  • Open Access

    Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial

    by Daniel H. Palmer, Richard Jackson, Christoph Springfeld, Paula Ghaneh, Charlotte Rawcliffe, Christopher M. Halloran, Olusola Faluyi, David Cunningham, Jonathan Wadsley, Suzanne Darby, et al.

    PURPOSE: The ESPAC4 trial showed that adjuvant chemotherapy with gemcitabine plus capecitabine (GemCap) produced longer overall survival (OS) than gemcitabine monotherapy. Subsequently, the PRODIGE24-CCTG PA.6 trial showed even longer survival for modified fluorouracil, folinic acid, irinotecan, and oxaliplatin (mFOLFIRINOX) than gemcitabine but had more restrictive eligibility criteria. Our aim was to analyze the ESPAC4 survival on long-term follow-up. METHODS: The OS of 732 ESPAC4 patients comparing 367 randomly assigned to gemcitabine and 365 to GemCap was previously reported after a median follow-up time of 43.2 months (95% CI, 39.7 to 45.5) and 458 deaths. Analysis was now carried out after a median follow-up of 104 months (101-108) and 566 deaths. RESULTS: The median OS was 29.5 months (27.5-32.1) for all patients, 28.4 months (25.2-32.0) in the gemcitabine group and 31.6 months (26.5-38.0) in the GemCap group (hazard ratio [HR], 0.83 [0.71 to 0.98]; P = .031). R0 patients given gemcitabine had a median survival of 32.2 months (27.9-41.6) compared with 49.9 months (39.0-82.3) for those given GemCap (HR, 0.63 [0.47 to 0.84]; P = .002). Lymph node-negative patients had significantly higher 5 year OS rates on GemCap (59% [49%-71%]) than gemcitabine (53% [42%-66%]; HR, 0.63 [0.41 to 0.98]; P = .04) but not those with positive lymph nodes ( P = .225). The OS advantage for GemCap was retained in the PRODIGE24 subgroup of 193 (26.4%) ESPAC4 patients not eligible for PRODIGE24 with a median survival of 20.7 (16.2-27.3) months in patients allocated to gemcitabine compared with 25.9 (22.3-30.2) months for ineligible patients allocated to GemCap (HR, 0.71 [95% CI, 0.52 to 0.98]; χ 2 log-rank-1df = 4.31; P = .038). CONCLUSION: GemCap is a standard option for patients not eligible for mFOLFIRINOX. Exploratory evidence suggests that GemCap may be particularly efficacious in R0 patients and also in lymph node-negative patients.